Does the media prefer QDEL or ICUI?

In the previous week, QuidelOrtho had 3 more articles in the media than ICU Medical. MarketBeat recorded 4 mentions for QuidelOrtho and 1 mentions for ICU Medical. ICU Medical's average media sentiment score of 1.15 beat QuidelOrtho's score of 0.59 indicating that ICU Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive ICU Medical 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HAE or QDEL?

In the previous week, Haemonetics had 10 more articles in the media than QuidelOrtho. MarketBeat recorded 14 mentions for Haemonetics and 4 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.59 beat Haemonetics' score of -0.21 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral QuidelOrtho 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer QDEL or XRAY?

In the previous week, QuidelOrtho had 2 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 4 mentions for QuidelOrtho and 2 mentions for DENTSPLY SIRONA. DENTSPLY SIRONA's average media sentiment score of 0.88 beat QuidelOrtho's score of 0.59 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive DENTSPLY SIRONA 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NEOG or QDEL more profitable?

QuidelOrtho has a net margin of -45.57% compared to Neogen's net margin of -69.93%. QuidelOrtho's return on equity of 4.25% beat Neogen's return on equity. Company Net Margins Return on Equity Return on Assets Neogen -69.93% 2.35% 1.46% QuidelOrtho -45.57% 4.25% 1.56%

Does the media refer more to NEOG or QDEL?

In the previous week, Neogen had 2 more articles in the media than QuidelOrtho. MarketBeat recorded 6 mentions for Neogen and 4 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.59 beat Neogen's score of 0.33 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neogen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral QuidelOrtho 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to STAA or QDEL?

In the previous week, QuidelOrtho had 1 more articles in the media than STAAR Surgical. MarketBeat recorded 4 mentions for QuidelOrtho and 3 mentions for STAAR Surgical. QuidelOrtho's average media sentiment score of 0.59 beat STAAR Surgical's score of 0.51 indicating that QuidelOrtho is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STAAR Surgical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive QuidelOrtho 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

QuidelOrtho (QDEL) Competitors

$15.30 +1.70 (+12.50%)

Closing price 04:00 PM Eastern

Extended Trading

$15.10 -0.20 (-1.33%)

As of 05:08 PM Eastern

Compare

QDEL vs. ICUI, HAE, XRAY, NEOG, and STAA

Should you buy QuidelOrtho stock or one of its competitors? MarketBeat compares QuidelOrtho with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with QuidelOrtho include ICU Medical (ICUI), Haemonetics (HAE), DENTSPLY SIRONA (XRAY), Neogen (NEOG), and STAAR Surgical (STAA). These companies are all part of the "health care supplies" industry.

How does QuidelOrtho compare to ICU Medical?

QuidelOrtho (NASDAQ:QDEL) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

QuidelOrtho has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, ICU Medical has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

ICU Medical has lower revenue, but higher earnings than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.38	-$1.13B	-$17.82	N/A
ICU Medical	$2.23B	1.51	$730K	$1.85	72.94

ICU Medical has a net margin of 2.15% compared to QuidelOrtho's net margin of -45.57%. ICU Medical's return on equity of 7.50% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-45.57%	4.25%	1.56%
ICU Medical	2.15%	7.50%	3.91%

QuidelOrtho presently has a consensus price target of $14.88, suggesting a potential downside of 2.78%. ICU Medical has a consensus price target of $168.00, suggesting a potential upside of 24.51%. Given ICU Medical's stronger consensus rating and higher possible upside, analysts plainly believe ICU Medical is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ICU Medical	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, QuidelOrtho had 3 more articles in the media than ICU Medical. MarketBeat recorded 4 mentions for QuidelOrtho and 1 mentions for ICU Medical. ICU Medical's average media sentiment score of 1.15 beat QuidelOrtho's score of 0.59 indicating that ICU Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
ICU Medical	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 96.1% of ICU Medical shares are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by insiders. Comparatively, 2.1% of ICU Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ICU Medical beats QuidelOrtho on 13 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to Haemonetics?

Haemonetics (NYSE:HAE) and QuidelOrtho (NASDAQ:QDEL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

Haemonetics has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Haemonetics has a net margin of 7.29% compared to QuidelOrtho's net margin of -45.57%. Haemonetics' return on equity of 27.30% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Haemonetics	7.29%	27.30%	9.59%
QuidelOrtho	-45.57%	4.25%	1.56%

In the previous week, Haemonetics had 10 more articles in the media than QuidelOrtho. MarketBeat recorded 14 mentions for Haemonetics and 4 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.59 beat Haemonetics' score of -0.21 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Haemonetics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
QuidelOrtho	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Haemonetics has higher earnings, but lower revenue than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haemonetics	$1.33B	2.38	$97.31M	$2.02	34.58
QuidelOrtho	$2.73B	0.38	-$1.13B	-$17.82	N/A

99.7% of Haemonetics shares are held by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are held by institutional investors. 1.8% of Haemonetics shares are held by company insiders. Comparatively, 1.1% of QuidelOrtho shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Haemonetics currently has a consensus target price of $77.11, suggesting a potential upside of 10.40%. QuidelOrtho has a consensus target price of $14.88, suggesting a potential downside of 2.78%. Given Haemonetics' stronger consensus rating and higher possible upside, equities analysts plainly believe Haemonetics is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haemonetics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Haemonetics beats QuidelOrtho on 14 of the 17 factors compared between the two stocks.

How does QuidelOrtho compare to DENTSPLY SIRONA?

QuidelOrtho (NASDAQ:QDEL) and DENTSPLY SIRONA (NASDAQ:XRAY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

QuidelOrtho has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, DENTSPLY SIRONA has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

DENTSPLY SIRONA has higher revenue and earnings than QuidelOrtho. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.38	-$1.13B	-$17.82	N/A
DENTSPLY SIRONA	$3.68B	0.54	-$598M	-$3.15	N/A

QuidelOrtho presently has a consensus price target of $14.88, suggesting a potential downside of 2.78%. DENTSPLY SIRONA has a consensus price target of $13.55, suggesting a potential upside of 37.10%. Given DENTSPLY SIRONA's stronger consensus rating and higher probable upside, analysts clearly believe DENTSPLY SIRONA is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
DENTSPLY SIRONA	3 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.00

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 95.7% of DENTSPLY SIRONA shares are held by institutional investors. 1.1% of QuidelOrtho shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

DENTSPLY SIRONA has a net margin of -17.06% compared to QuidelOrtho's net margin of -45.57%. DENTSPLY SIRONA's return on equity of 18.83% beat QuidelOrtho's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-45.57%	4.25%	1.56%
DENTSPLY SIRONA	-17.06%	18.83%	5.13%

In the previous week, QuidelOrtho had 2 more articles in the media than DENTSPLY SIRONA. MarketBeat recorded 4 mentions for QuidelOrtho and 2 mentions for DENTSPLY SIRONA. DENTSPLY SIRONA's average media sentiment score of 0.88 beat QuidelOrtho's score of 0.59 indicating that DENTSPLY SIRONA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
DENTSPLY SIRONA	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DENTSPLY SIRONA beats QuidelOrtho on 12 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to Neogen?

Neogen (NASDAQ:NEOG) and QuidelOrtho (NASDAQ:QDEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Neogen has higher earnings, but lower revenue than QuidelOrtho. Neogen is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neogen	$894.66M	2.22	-$1.09B	-$2.80	N/A
QuidelOrtho	$2.73B	0.38	-$1.13B	-$17.82	N/A

QuidelOrtho has a net margin of -45.57% compared to Neogen's net margin of -69.93%. QuidelOrtho's return on equity of 4.25% beat Neogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neogen	-69.93%	2.35%	1.46%
QuidelOrtho	-45.57%	4.25%	1.56%

In the previous week, Neogen had 2 more articles in the media than QuidelOrtho. MarketBeat recorded 6 mentions for Neogen and 4 mentions for QuidelOrtho. QuidelOrtho's average media sentiment score of 0.59 beat Neogen's score of 0.33 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neogen	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
QuidelOrtho	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Neogen presently has a consensus price target of $10.67, indicating a potential upside of 16.96%. QuidelOrtho has a consensus price target of $14.88, indicating a potential downside of 2.78%. Given Neogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Neogen is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neogen	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

96.7% of Neogen shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 0.6% of Neogen shares are owned by company insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Neogen has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Summary

Neogen and QuidelOrtho tied by winning 8 of the 16 factors compared between the two stocks.

How does QuidelOrtho compare to STAAR Surgical?

STAAR Surgical (NASDAQ:STAA) and QuidelOrtho (NASDAQ:QDEL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

96.7% of STAAR Surgical shares are owned by institutional investors. Comparatively, 99.0% of QuidelOrtho shares are owned by institutional investors. 39.9% of STAAR Surgical shares are owned by insiders. Comparatively, 1.1% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

STAAR Surgical has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, QuidelOrtho has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

STAAR Surgical has higher earnings, but lower revenue than QuidelOrtho. STAAR Surgical is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$239.44M	6.21	-$80.45M	-$0.43	N/A
QuidelOrtho	$2.73B	0.38	-$1.13B	-$17.82	N/A

STAAR Surgical currently has a consensus target price of $27.81, indicating a potential downside of 6.86%. QuidelOrtho has a consensus target price of $14.88, indicating a potential downside of 2.78%. Given QuidelOrtho's higher possible upside, analysts plainly believe QuidelOrtho is more favorable than STAAR Surgical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

STAAR Surgical has a net margin of -7.24% compared to QuidelOrtho's net margin of -45.57%. QuidelOrtho's return on equity of 4.25% beat STAAR Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	-7.24%	3.31%	2.55%
QuidelOrtho	-45.57%	4.25%	1.56%

In the previous week, QuidelOrtho had 1 more articles in the media than STAAR Surgical. MarketBeat recorded 4 mentions for QuidelOrtho and 3 mentions for STAAR Surgical. QuidelOrtho's average media sentiment score of 0.59 beat STAAR Surgical's score of 0.51 indicating that QuidelOrtho is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
QuidelOrtho	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

STAAR Surgical beats QuidelOrtho on 9 of the 16 factors compared between the two stocks.

Get QuidelOrtho News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QDEL vs. The Competition

Export

Metric	QuidelOrtho	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04B	$8.25B	$6.44B	$12.46B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	-0.86	15.68	23.87	24.36
Price / Sales	0.38	7.13	521.52	117.07
Price / Cash	0.70	17.10	41.27	57.13
Price / Book	0.54	3.63	9.99	6.73
Net Income	-$1.13B	$224.05M	$3.56B	$337.03M
7 Day Performance	17.06%	0.30%	-0.89%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.78%
1 Year Performance	-50.77%	2.90%	28.77%	33.98%

QuidelOrtho Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QDEL QuidelOrtho	1.8378 of 5 stars	$15.30 +12.5%	$14.88 -2.8%	-55.1%	$1.04B	$2.73B	N/A	6,500	Gap Up
ICUI ICU Medical	3.832 of 5 stars	$131.64 -2.8%	$168.00 +27.6%	0.0%	$3.38B	$2.23B	71.16	13,000
HAE Haemonetics	2.4315 of 5 stars	$67.37 -0.6%	$77.11 +14.5%	-5.3%	$3.08B	$1.33B	33.35	3,009	Analyst Revision
XRAY DENTSPLY SIRONA	4.4658 of 5 stars	$10.02 -4.3%	$13.82 +37.9%	-39.3%	$2.10B	$3.68B	N/A	14,000	Analyst Forecast
NEOG Neogen	1.7537 of 5 stars	$8.92 -0.6%	$10.67 +19.6%	+46.8%	$1.95B	$894.66M	N/A	2,110	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QDEL) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

QuidelOrtho (QDEL) Competitors

QDEL vs. ICUI, HAE, XRAY, NEOG, and STAA

How does QuidelOrtho compare to ICU Medical?

Summary

How does QuidelOrtho compare to Haemonetics?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Summary

How does QuidelOrtho compare to Neogen?

Summary

How does QuidelOrtho compare to STAAR Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

QuidelOrtho (QDEL) Competitors

QDEL vs. ICUI, HAE, XRAY, NEOG, and STAA

How does QuidelOrtho compare to ICU Medical?

Which has more risk & volatility, QDEL or ICUI?

Which has better earnings & valuation, QDEL or ICUI?

Is QDEL or ICUI more profitable?

Do analysts recommend QDEL or ICUI?

Does the media prefer QDEL or ICUI?

Do insiders and institutionals hold more shares of QDEL or ICUI?

Summary

How does QuidelOrtho compare to Haemonetics?

Which has more volatility and risk, HAE or QDEL?

Is HAE or QDEL more profitable?

Does the media prefer HAE or QDEL?

Which has better valuation and earnings, HAE or QDEL?

Do institutionals & insiders have more ownership in HAE or QDEL?

Do analysts rate HAE or QDEL?

Summary

How does QuidelOrtho compare to DENTSPLY SIRONA?

Which has more volatility & risk, QDEL or XRAY?

Which has higher earnings & valuation, QDEL or XRAY?

Do analysts rate QDEL or XRAY?

Do institutionals and insiders have more ownership in QDEL or XRAY?

Is QDEL or XRAY more profitable?

Does the media prefer QDEL or XRAY?

Summary

How does QuidelOrtho compare to Neogen?

Which has better earnings & valuation, NEOG or QDEL?

Is NEOG or QDEL more profitable?

Does the media refer more to NEOG or QDEL?

Do analysts rate NEOG or QDEL?

Do institutionals & insiders have more ownership in NEOG or QDEL?

Which has more risk and volatility, NEOG or QDEL?

Summary

How does QuidelOrtho compare to STAAR Surgical?

Do insiders & institutionals have more ownership in STAA or QDEL?

Which has more risk & volatility, STAA or QDEL?

Which has preferable valuation & earnings, STAA or QDEL?

Do analysts recommend STAA or QDEL?

Is STAA or QDEL more profitable?

Does the media refer more to STAA or QDEL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QDEL vs. The Competition

QuidelOrtho Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools